Elevated PSA
An elevated PSA result can be alarming, but it does not automatically mean you have prostate cancer—in fact, roughly 3 out of 4 men with elevated PSA do not have cancer. Dr. Radtke uses advanced tools including prostate MRI, biomarker testing, and MRI-fusion biopsy to determine exactly what your PSA level means and guide the right next steps.
Request a ConsultationWhat Is an Elevated PSA?
Prostate-specific antigen (PSA) is a protein produced naturally by the prostate gland. Every man has some PSA in his blood. A PSA blood test measures the amount of this protein, and it is one of the most important tools for early detection of prostate cancer. However, PSA is prostate-specific, not cancer-specific—meaning many conditions other than cancer can cause your PSA to rise.
What Do the Numbers Mean?
There is no single “normal” PSA number that applies to every man. In general, a PSA below 4.0 ng/mL has traditionally been considered within the normal range, but context matters significantly. Men in their 40s and 50s typically have a PSA of 0.6–0.7 ng/mL, and a reading above 2.5 ng/mL in this age group may warrant further attention. For men in their 60s and older, a PSA up to 4.0 ng/mL is more common due to natural prostate growth with age.
A PSA between 4.0 and 10.0 ng/mL is sometimes called the “gray zone.” In this range, approximately 25% of men will be found to have prostate cancer on biopsy—meaning 75% do not have cancer. Even with a PSA above 10.0, cancer is found in only about half of cases. These numbers illustrate why a single PSA reading should never be interpreted in isolation.
Common Causes of Elevated PSA
Many benign (non-cancerous) conditions can raise your PSA level, including:
- Benign prostatic hyperplasia (BPH) — An enlarged prostate is the single most common cause of elevated PSA. A larger prostate simply produces more PSA protein. Learn more about BPH →
- Prostatitis — Inflammation or infection of the prostate can cause a significant, often temporary, spike in PSA.
- Urinary tract infection (UTI) — Infections in the urinary system can irritate the prostate and elevate PSA.
- Recent ejaculation — Sexual activity within 24–48 hours before a blood draw can temporarily increase PSA levels. Patients are typically advised to avoid ejaculation for 48 hours before a PSA test.
- Prostate manipulation — A digital rectal exam, catheter placement, prostate biopsy, or even prolonged cycling can cause short-term PSA elevations.
- Certain medications — Testosterone replacement therapy and some other medications can raise PSA.
- Age — PSA levels naturally rise as men get older, even in healthy men with no prostate disease.
Because so many factors can influence PSA, a single elevated reading should always be interpreted carefully and in context—never as a standalone diagnosis.
When Should You Be Concerned?
While most elevated PSA results turn out to be caused by benign conditions, certain patterns are more concerning and deserve prompt urological evaluation:
- A PSA that is significantly elevated (above 10.0 ng/mL)
- A PSA that is rising quickly over time (a steep upward trend on repeat testing)
- An abnormal digital rectal exam in combination with elevated PSA
- A family history of prostate cancer, especially in a father or brother
- African American men, who have a higher baseline risk of prostate cancer and are recommended to begin screening discussions as early as age 40
If any of these factors apply to you, Dr. Radtke will work with you to determine the best next steps. The goal is always to detect cancer early when it is most treatable, while avoiding unnecessary procedures when cancer is unlikely.
Tools We Use to Get Answers
Repeat PSA & Free PSA
If your initial PSA is elevated, the first step is often to repeat the test in 6–8 weeks to confirm the result and rule out temporary causes like infection or recent activity. We may also measure your free PSA—the percentage of PSA circulating unbound in your blood. Cancer tends to produce more bound PSA, while benign conditions produce more free PSA. A free-to-total PSA ratio above 25% suggests a benign cause is likely; a ratio below 10% raises more concern and typically prompts further workup.
PSA Density
PSA density is calculated by dividing your PSA level by the volume of your prostate (measured on ultrasound or MRI). A larger prostate naturally produces more PSA, so adjusting for prostate size helps distinguish between a big gland making a normal amount of PSA and a smaller gland producing a worrisome amount. A PSA density above 0.15 is generally considered more suspicious and may prompt additional evaluation or biopsy.
Prostate MRI
Multiparametric MRI (mpMRI) of the prostate has become a critical part of the modern evaluation. This advanced imaging can detect suspicious areas within the prostate and assign a PI-RADS score (1–5) that estimates the likelihood of clinically significant cancer. MRI helps determine whether a biopsy is needed and, if so, allows Dr. Radtke to target the biopsy precisely to the most concerning areas—a technique called MRI-fusion biopsy. Studies show that MRI-guided evaluation can reduce unnecessary biopsies while improving detection of cancers that actually need treatment.
Biomarker Testing
When PSA alone does not give a clear picture, newer blood and urine biomarker tests can help refine your risk. These include the 4Kscore (a blood test combining four PSA-related proteins with clinical factors), the Prostate Health Index (PHI) (which measures three forms of PSA for greater cancer specificity), and SelectMDx (a urine test detecting cancer-associated gene activity). These tools are especially useful in the PSA “gray zone” of 4–10 ng/mL, helping you and Dr. Radtke decide together whether biopsy is warranted or whether continued monitoring is the safer path.
MRI-Fusion Targeted Biopsy
If the evaluation points toward a meaningful risk of prostate cancer, a biopsy is the definitive way to determine whether cancer is present. Dr. Radtke uses MRI-fusion biopsy, which overlays MRI images onto real-time ultrasound to precisely target suspicious areas. This approach is more accurate than traditional random biopsy alone, improving detection of clinically significant cancers while reducing the chance of finding low-risk cancers that may never need treatment. The procedure is performed with local anesthesia and typically takes about 15–20 minutes.
Shared Decision-Making
The American Urological Association emphasizes that PSA-based screening and the decision to proceed with biopsy should always involve a conversation between doctor and patient. Dr. Radtke takes the time to explain your individual risk factors, review all available data, and discuss the pros and cons of each option. You are an active partner in every decision—there is no one-size-fits-all approach to an elevated PSA.
Your Evaluation Journey
PSA Found to Be Elevated
Your primary care provider or another physician identifies an elevated PSA level on routine blood work. You are referred to Dr. Radtke for urological evaluation. Before your visit, it is helpful to know that ejaculation within 48 hours and certain activities can temporarily raise PSA levels—an elevated number alone does not mean you have cancer.
Initial Consultation
Dr. Radtke reviews your complete PSA history, medical history, family history, medications, and any urinary symptoms. A digital rectal exam (DRE) is performed to check for prostate abnormalities. Together, you discuss your overall risk profile—including age, race, and family history—and determine whether a repeat PSA, free PSA ratio, or additional biomarker testing is the appropriate next step.
Risk Refinement
Depending on your risk profile, Dr. Radtke may order a repeat PSA with free PSA ratio, biomarker tests such as 4Kscore or Prostate Health Index (PHI), and/or a multiparametric MRI of the prostate. These tools work together to build a clearer picture of your individual cancer risk. In many cases, they provide enough reassurance that active monitoring alone—with periodic PSA checks—is the right approach, sparing you from an unnecessary biopsy.
Prostate Biopsy (If Indicated)
If the evaluation suggests a meaningful risk of clinically significant prostate cancer, Dr. Radtke performs an MRI-fusion targeted biopsy. This technique overlays MRI images onto real-time ultrasound to precisely sample suspicious areas identified on imaging, improving accuracy compared to traditional random biopsy. The procedure is performed with local anesthesia, takes approximately 15–20 minutes, and most patients return to normal activities the following day.
Results & Next Steps
Biopsy results are typically available within one to two weeks. Dr. Radtke will review the pathology findings with you in detail. If prostate cancer is found, he will explain the Gleason grade, cancer stage, and all available treatment options—from active surveillance to robotic radical prostatectomy. If the biopsy is negative, he will outline a personalized monitoring plan with periodic PSA checks and follow-up imaging so you can have ongoing peace of mind.
Contact & Appointments
Schedule an Appointment
Dr. Radtke sees patients through Prevea Health. You can book an appointment online or call our office directly.
Clinic Information
(920) 458-6664
Monday – Friday: 8:00 AM – 5:00 PM
Saturday – Sunday: Closed